VIP vs PNC27
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Vasoactive Intestinal Peptide, Aviptadil
VIP (vasoactive intestinal peptide) is a 28-amino-acid signaling peptide your own gut, nerves, and immune cells make. It is a natural anti-inflammatory and a potent vasodilator, and a synthetic version called aviptadil has been tested in humans for COVID-19 respiratory failure and pulmonary conditions. No VIP product is FDA-approved for the wellness or anti-aging uses it gets marketed for, and most of that human data is in lung disease, not in healthy people.
Also: PNC-27, p53-HDM2 Disruptor Peptide
PNC-27 is a 32-amino-acid lab-designed peptide that fuses a fragment of the tumor-suppressor protein p53 (residues 12 to 26) to a membrane-penetrating leader sequence. The interesting claim is that it kills cancer cells while leaving normal cells alone, by punching holes in the cancer cell membrane. It is a research compound only, with no approval and no human clinical trials.
Key Comparison Insights
- Both peptides belong to the Immune category, suggesting similar primary applications.
- VIP has stronger research evidence (Human Trials) compared to PNC27 (Animal Studies).
Detailed Comparison
| Attribute | VIP | PNC27 |
|---|---|---|
| Category | Immune | Immune |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | VIP works through two G-protein-coupled receptors, VPAC1 and VPAC2, which are spread across immune cells, the gut, blood vessels, and the brain. When VIP binds, the receptor raises intracellular cyclic AMP, and that signal relaxes smooth muscle (so blood vessels and airways dilate) and tamps down inflammatory signaling. On the immune side, that rise in cAMP blunts NF-kB activity and lowers pro-inflammatory cytokines like TNF-alpha, which is the basis for calling VIP an endogenous anti-inflammatory. The same pathway is why researchers looked at it for the runaway lung inflammation seen in severe COVID-19. It is a broadly active hormone, not a targeted single-tissue drug, which is part of why dosing it safely is tricky. | The hook is selectivity. Many cancer cells display the protein HDM-2 (the human version of MDM2) on their outer membrane, while most normal cells keep it tucked inside. PNC-27 carries the part of p53 that normally docks onto HDM-2, so it latches onto that membrane-bound HDM-2 on cancer cells. Once anchored there, the peptide's amphipathic helix-loop-helix structure inserts into the membrane and forms pores, causing the cell to rupture and die by necrosis rather than the slower apoptosis pathway. The peptide has also been reported to disrupt mitochondrial membranes after entering the cell. Normal cells that lack membrane HDM-2 are reported not to bind the peptide and survive, which is the basis for the selectivity claim. |
| Common Dosing | 50-100 mcg intranasal daily 1-2x daily, intranasal | No human dose - research compound only Not applicable - no human use |
| Administration | IV infusion, inhaled, or intranasal | IV injection in animal studies - not for human use |
| Typical Duration | Variable by indication | Research protocols only - no human use data |
| Best Time to Take | Morning or as directed | Per research protocol |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Most of the real human data on VIP comes from aviptadil, the synthetic analog. A randomized controlled trial of intravenous aviptadil in critically ill COVID-19 patients with respiratory failure (about 196 patients, published in Critical Care Medicine in 2022) did not hit its primary endpoint of being alive and free of respiratory failure at 60 days, though there were exploratory signals worth following up. Larger and inhaled formulations were studied through the ACTIV-3b/TESICO program, and the overall picture is mixed rather than a clear win. Beyond the lungs, VIP and its VPAC receptors are studied in rheumatoid arthritis, pulmonary arterial hypertension, and other inflammatory conditions, but that work is largely mechanistic or early-stage. There is no good human evidence supporting the anti-aging, longevity, or general wellness claims VIP is sold for online. Bottom line: a genuinely interesting immune-modulating peptide with real trials, but the trials were in serious illness and did not establish it as an effective therapy. | The mechanistic story is backed by real peer-reviewed work, most notably a 2010 paper in PNAS (Sarafraz-Yazdi and colleagues) showing PNC-27 adopts an HDM-2-binding shape and kills cancer cells by binding HDM-2 in their membranes, plus a 2010 study confirming the intact peptide causes tumor cell lysis. Follow-up work, including a 2022 paper in Biomedicines, reinforced the membrane-pore model and selectivity in cell lines and showed transfecting membrane HDM-2 into normal cells makes them vulnerable too. Crucially, all of this is in vitro and in animal models. There are no completed human clinical trials demonstrating safety or anticancer benefit in patients, so any claim that PNC-27 treats cancer in people is not supported. It is a genuinely intriguing preclinical anticancer concept that has not crossed into proven human therapy, and self-experimentation is not justified by the data. |
Frequently Asked Questions: VIP vs PNC27
What is the difference between VIP and PNC27?
VIP is a immune peptide that vip (vasoactive intestinal peptide) is a 28-amino-acid signaling peptide your own gut, nerves, and immune cells make. it is a natural anti-inflammatory and a potent vasodilator, and a synthetic version called aviptadil has been tested in humans for covid-19 respiratory failure and pulmonary conditions. no vip product is fda-approved for the wellness or anti-aging uses it gets marketed for, and most of that human data is in lung disease, not in healthy people. PNC27 is a immune peptide that pnc-27 is a 32-amino-acid lab-designed peptide that fuses a fragment of the tumor-suppressor protein p53 (residues 12 to 26) to a membrane-penetrating leader sequence. the interesting claim is that it kills cancer cells while leaving normal cells alone, by punching holes in the cancer cell membrane. it is a research compound only, with no approval and no human clinical trials. The main differences lie in their mechanisms of action and clinical applications.
Which is better, VIP or PNC27?
Neither is universally "better" - the choice depends on your specific goals. VIP is typically used for immune purposes, while PNC27 is used for immune. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can VIP and PNC27 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using VIP and PNC27 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.